CCA
BMRN icon

Clearwater Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clearwater Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-172
Closed -$14K – 225
2018
Q1 		$14K Buy
+172
New +$14.8K ﹤0.01% 436

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Clearwater Capital Advisors's BMRN Position: Q2 2018 in Review

Clearwater Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 172 shares — an estimated $14K sold.

Clearwater Capital Advisors first reported a position in BMRN in Q1 2018 and held it in 1 quarter. The position peaked at $14K in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • Clearwater Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Clearwater Capital Advisors sold 172 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $14K.
  • Clearwater Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Clearwater Capital Advisors's BioMarin Pharmaceuticals position peaked at $14K in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Clearwater Capital Advisors's 13F filing for Q2 2018, filed 16 Aug 2018.